<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900406</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BMT 0664</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-BMT-0664</secondary_id>
    <secondary_id>VU-VICC-IRB-061215</secondary_id>
    <nct_id>NCT00900406</nct_id>
  </id_info>
  <brief_title>Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant</brief_title>
  <official_title>Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of blood, urine, and tissue from patients
      undergoing a donor stem cell transplant to test in the laboratory may help the study of
      graft-versus-host disease in the future.

      PURPOSE: This research study is collecting and storing tissue and DNA samples from patients
      undergoing a donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To establish a DNA bank from donor and recipient (prior to transplant) peripheral blood
           for SNP studies.

        -  To establish a tissue bank for gene expression studies using donor and recipient
           (post-transplant) peripheral blood samples.

        -  To establish a tissue bank for proteomic studies using donor and recipient blood and
           urine samples.

        -  To establish a tissue bank for various studies using biopsy specimens.

        -  To establish a tissue bank for flow cytometric studies using recipient
           (post-transplant), and sample from stem cell product.

      OUTLINE: Peripheral blood samples are collected from donors prior to stem cell mobilization
      and from patients prior to starting preparative regimen. Samples are studied by single
      nucleotide polymorphism (SNP) analysis, SNP array, proteomic analysis, gene expression, and
      other immunological laboratory methods. Blood, urine, and tissue samples are preserved for
      future studies. Extra skin biopsies and gastrointestinal biopsies are performed at diagnosis
      of graft-vs-host disease and preserved in a tissue bank for flow cytometric studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA bank from donor and recipient (prior to transplant) peripheral blood for single nucleotide polymorphism studies</measure>
    <time_frame>Completion of transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue bank for gene expression studies using donor and recipient (post-transplant) peripheral blood samples</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue bank for proteomic studies using donor and recipient blood and urine samples</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue bank for flow cytometric studies using recipient (post-transplant), and sample from stem cell product</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">190</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Gestational Trophoblastic Tumor</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Blood collection</description>
    <arm_group_label>Recipients of stem cells with graft versus host disease</arm_group_label>
    <arm_group_label>Recipients of stem cells at risk of graft versus host disease</arm_group_label>
    <arm_group_label>Donator of stem cells</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People who have received a stem cell transplant and are being treated for graft versus host
        disease or are at risk of graft versus host disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Approved for allogeneic stem cell transplantation

          -  Sample of the stem cells from donor must meet 1 of the following criteria:

               -  Total peripheral blood stem cell dose &gt; 5 X10^6 CD34+ cells/kg

               -  Marrow cell dose &gt; 3 X 10^8 nucleated cells/kg

        PATIENT CHARACTERISTICS:

          -  Platelet count &gt; 50,000/mmÂ³ (for patients undergoing endoscopic biopsies)

          -  INR &lt; 1.5 (for patients undergoing endoscopic biopsies)

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madan Jagasia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 4, 2012</last_update_submitted>
  <last_update_submitted_qc>November 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Madan Jagasia, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine; Director, Outpatient Transplant Program; Section Chief, Hematology and Stem Cell Transplant;</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

